First Trust Advisors’s Takeda Pharmaceutical TAK Stock Holding History

First Trust Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9M	Buy	2,114,912 +143,838	+7%	+$2.38M	0.02%	772
2026 Q1	$36.5M	Sell	1,971,074 -411,555	-17%	-$7.22M	0.03%	708
2025 Q4	$37.1M	Sell	2,382,629 -134,810	-5%	-$1.93M	0.03%	692
2025 Q3	$36.9M	Sell	2,517,439 -84,369	-3%	-$1.25M	0.03%	701
2025 Q2	$40.2M	Sell	2,601,808 -154,147	-6%	-$2.28M	0.03%	651
2025 Q1	$41M	Sell	2,755,955 -484,977	-15%	-$6.8M	0.04%	621
2024 Q4	$42.9M	Buy	3,240,932 +62,718	+2%	+$862K	0.04%	596
2024 Q3	$45.2M	Buy	+3,178,214	New	+$45.1M	0.04%	536
2023 Q4	–	Sell	-233,119	Closed	-$3.61M	–	2433
2023 Q3	$3.61M	Buy	233,119 +68,066	+41%	+$1.05M	﹤0.01%	1407
2023 Q2	$2.59M	Sell	165,053 -243,710	-60%	-$3.99M	﹤0.01%	1577
2023 Q1	$6.74M	Buy	408,763 +179,939	+79%	+$2.87M	0.01%	1106
2022 Q4	$3.57M	Sell	228,824 -54,875	-19%	-$766K	﹤0.01%	1399
2022 Q3	$3.68M	Sell	283,699 -46,594	-14%	-$648K	﹤0.01%	1355
2022 Q2	$4.64M	Sell	330,293 -457,665	-58%	-$6.53M	0.01%	1265
2022 Q1	$11.3M	Sell	787,958 -47,098	-6%	-$692K	0.01%	1012
2021 Q4	$11.4M	Sell	835,056 -1,045,939	-56%	-$14.7M	0.01%	1009
2021 Q3	$30.8M	Buy	1,880,995 +336,324	+22%	+$5.65M	0.03%	623
2021 Q2	$26M	Sell	1,544,671 -315,586	-17%	-$5.37M	0.03%	668
2021 Q1	$34M	Buy	+1,860,257	New	+$33.5M	0.04%	529
2020 Q3	–	Sell	-1,396,270	Closed	-$25M	–	2473
2020 Q2	$25M	Sell	1,396,270 -43,557	-3%	-$782K	0.04%	495
2020 Q1	$21.9M	Sell	1,439,827 -588,092	-29%	-$10.7M	0.05%	477
2019 Q4	$40M	Sell	2,027,919 -13,214	-0.6%	-$253K	0.07%	436
2019 Q3	$35.1M	Buy	2,041,133 +385,573	+23%	+$6.67M	0.07%	432
2019 Q2	$29.3M	Sell	1,655,560 -967,723	-37%	-$17.6M	0.06%	450
2019 Q1	$53.4M	Buy	+2,623,283	New	+$52.8M	0.11%	237

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

First Trust Advisors's TAK Position: Q2 2026 in Review

First Trust Advisors increased its Takeda Pharmaceutical (TAK) stake by 7.3% in Q2 2026, buying an estimated $2.38M and bringing the position to 2,114,912 shares worth $33.9M. The position accounts for 0.02% of the portfolio, ranked #772.

First Trust Advisors first reported a position in TAK in Q1 2019 and has held it in 25 quarters since. The position peaked at $53.4M in Q1 2019. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

First Trust Advisors held 2,114,912 shares of Takeda Pharmaceutical worth $33.9M as of Q2 2026.
First Trust Advisors bought 143,838 Takeda Pharmaceutical shares in Q2 2026, an estimated $2.38M.
Takeda Pharmaceutical made up 0.02% of First Trust Advisors's portfolio in Q2 2026, its #772 holding.
First Trust Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 25 quarters since.
First Trust Advisors's Takeda Pharmaceutical position peaked at $53.4M in Q1 2019.
375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.